By Tony Fong

NEW YORK (GenomeWeb News) – A UK firm founded three years ago is looking to shake up the BRCA testing market.

In mid-2010, NewGene, based in Newcastle upon Tyne, launched its next-generation sequencing-based BRCA1 and BRCA2 testing service for breast cancer in the UK. Initially, the test is being targeted to patients with a family history of breast cancer with a longer-term goal of developing it as a general screen for the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.